Premium
Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient
Author(s) -
Baraniak Ilona Anna,
Reeves Matthew B.,
Griffiths Paul D.
Publication year - 2018
Publication title -
reviews in medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.06
H-Index - 90
eISSN - 1099-1654
pISSN - 1052-9276
DOI - 10.1002/rmv.1958
Subject(s) - human cytomegalovirus , cytomegalovirus , transmission (telecommunications) , immunization , medicine , immunology , virology , monoclonal antibody , virus , active immunization , antibody , herpesviridae , computer science , viral disease , telecommunications
Summary In this review article, we consider results suggesting that transmission of human cytomegalovirus (HCMV) from a donor of a solid organ to an immunologically naive individual can be reduced. Two randomized controlled trials have been conducted recently, one of active immunization of recipients pretransplant and another of passive immunization with monoclonal antibodies specific for HCMV given at the time of transplant. Although the available data are encouraging—providing evidence of a reduction in the incidence of HCMV viraemia—they fall short of what would be required to prove definitively that transmission has been completely prevented. Here, we reflect on these studies and propose a set of 5 criteria, which, if satisfied in the future, could be taken as proof that active and/or passive immunization against HCMV effectively interrupts transmission of virus from the donor. We suggest that these criteria are considered when designing future randomized controlled trials.